- Home
- VUZI vs PRQR Comparison
VUZI vs PRQR Comparison
Compare VUZI & PRQR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VUZI
- PRQR
- Stock Information
- Founded
- VUZI 1997
- PRQR 2012
- Country
- VUZI United States
- PRQR Netherlands
- Employees
- VUZI N/A
- PRQR N/A
- Industry
- VUZI Industrial Machinery/Components
- PRQR Biotechnology: Pharmaceutical Preparations
- Sector
- VUZI Technology
- PRQR Health Care
- Exchange
- VUZI Nasdaq
- PRQR Nasdaq
- Market Cap
- VUZI 267.1M
- PRQR 289.7M
- IPO Year
- VUZI N/A
- PRQR 2014
- Fundamental
- Price
- VUZI $3.39
- PRQR $2.59
- Analyst Decision
- VUZI
- PRQR Strong Buy
- Analyst Count
- VUZI 0
- PRQR 7
- Target Price
- VUZI N/A
- PRQR $8.14
- AVG Volume (30 Days)
- VUZI 2.0M
- PRQR 648.4K
- Earning Date
- VUZI 11-13-2025
- PRQR 11-07-2025
- Dividend Yield
- VUZI N/A
- PRQR N/A
- EPS Growth
- VUZI N/A
- PRQR N/A
- EPS
- VUZI N/A
- PRQR N/A
- Revenue
- VUZI $5,534,768.00
- PRQR $20,129,184.00
- Revenue This Year
- VUZI $22.67
- PRQR N/A
- Revenue Next Year
- VUZI $80.00
- PRQR N/A
- P/E Ratio
- VUZI N/A
- PRQR N/A
- Revenue Growth
- VUZI N/A
- PRQR 8.65
- 52 Week Low
- VUZI $0.85
- PRQR $1.07
- 52 Week High
- VUZI $5.79
- PRQR $4.21
- Technical
- Relative Strength Index (RSI)
- VUZI 47.72
- PRQR 49.69
- Support Level
- VUZI $3.27
- PRQR $2.61
- Resistance Level
- VUZI $3.64
- PRQR $3.00
- Average True Range (ATR)
- VUZI 0.25
- PRQR 0.25
- MACD
- VUZI -0.10
- PRQR -0.03
- Stochastic Oscillator
- VUZI 13.64
- PRQR 23.88
About VUZI Vuzix Corporation
Vuzix Corp is engaged in the design, manufacture, and marketing of Artificial Intelligence (AI)-powered Smart Glasses, Waveguides, and Augmented Reality (AR) technologies. Its solutions serve the enterprise, medical, defense, security, and select consumer markets, offering cutting-edge wearable computing and display technologies that enhance productivity and operational efficiency. Its products include near-eye displays (NEDs), heads-up displays (HUDs), and wearable computing devices. Geographically, the company generates a majority of its revenue from the United States and also has a presence in Japan, the Netherlands, and other countries.
About PRQR ProQR Therapeutics N.V.
ProQR Therapeutics NV is a biopharmaceutical company. It discovers and develops RNA therapeutics for patients with severe genetic rare diseases such as cystic fibrosis, Leber congenital amaurosis type 10, and dystrophic epidermolysis bullosa. The only reportable segment of the company is the discovery and development of different, RNA-based therapeutics.